Trastuzumab Biosimilar on Track for Approval [News in Brief]
An FDA expert panel recommended approval of Mylan's MYL-14010, a biosimilar candidate for Genentech's trastuzumab, putting it on track to become the first approved biosimilar for cancer. Experts predict that biosimilars will lead to lower drug prices, but caution that the savings won't be as dramatic as that seen with generics. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
CAR T Cells Drive CLL Remissions [News in Brief]
A new study shows that chimeric antigen receptor T cells produce objective responses in 71% of patients with chronic lymphocytic leukemia whose disease progressed despite receiving ibrutinib or who are unable to tolerate the drug. Cancer cells were undetectable in the bone marrow in 81% of tested patients, and 64% of tested patients showed complete lymph node responses. Most patients experienced adverse effects, however. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
$10M Gift Supports "Data Recycling" at UCSF [News in Brief]
The University of California, San Francisco's Institute for Computational Health Sciences has received a $10 million gift to support "data recycling" investigations. The approach to medical research involves mining existing data to potentially uncover new uses for existing drugs and help improve clinical care. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Enasidenib Approved for AML, but Best Uses Unclear [News in Brief]
The FDA approved the targeted therapy enasidenib for patients with refractory or relapsed acute myeloid leukemia with mutant IDH2. The drug produces remissions in some patients and may reduce the need for blood transfusions, although researchers acknowledge that the FDA's approval came with less supporting evidence than usual. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Mapping Out Cancer Dependencies [News in Brief]
Through large-scale RNAi screens, two groups of researchers have documented, in depth, the molecular players essential for tumor cell viability. Their cancer "dependency maps," which are publicly accessible, should aid drug discovery efforts by pinpointing therapeutic targets that merit developmental focus. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Equipping NK Cells with CARs [News in Brief]
Adding a chimeric antigen receptor (CAR) to natural killer (NK) cells is garnering interest as a therapeutic strategy because this immune cell type doesn't cause graft-versus-host disease, making its widespread, off-the-shelf use feasible. Based on promising preclinical data, a phase I/II trial of one such CAR NK-cell therapy is under way, targeting CD19 in hematologic malignancies. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
First-Ever CAR T-cell Therapy Approved in U.S. [News in Brief]
The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice. (Source: Cancer Discovery)
Source: Cancer Discovery - October 2, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers [Research Articles]
This article is highlighted in the In This Issue feature, p. 920 (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Authors: Bialucha, C. U., Collins, S. D., Li, X., Saxena, P., Zhang, X., Dürr, C., Lafont, B., Prieur, P., Shim, Y., Mosher, R., Lee, D., Ostrom, L., Hu, T., Bilic, S., Rajlic, I. L., Capka, V., Jiang, W., Wagner, J. P., Elliott, G., Veloso, A., Piel, J. C Tags: Research Articles Source Type: research
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma [Research Articles]
This article is highlighted in the In This Issue feature, p. 920 (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Authors: Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., Codega, P., Nichol, D., Clark, O., Hsieh, W.-Y., Rohle, D., Rosenblum, M., Viale, A., Tabar, V. S., Brennan, C. W., Gavrilovic, I. T., Kaley, T. J., Nolan, C. P., Omuro, A., Pen Tags: Research Articles Source Type: research
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition [Research Articles]
This article is highlighted in the In This Issue feature, p. 920 (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Authors: Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., Fowler, G., Ebbs, B., Flohr, P., Seed, G., Rodrigues, D. N., Boysen, G., Bertan, C., Atkin, M., Clarke, M., Crespo, M., Figuei Tags: Research Articles Source Type: research
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors [Research Briefs]
This article is highlighted in the In This Issue feature, p. 920 (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Authors: Quigley, D., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., Beja, K., Annala, M., Das, R., Diolaiti, M., Pritchard, C., Thomas, G., Tomlins, S., Knudsen, K., Lord, C. J., Ryan, C., Youngren, Tags: Research Briefs Source Type: research
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma [Research Briefs]
This article is highlighted in the In This Issue feature, p. 920 (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Authors: Kondrashova, O., Nguyen, M., Shield-Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G.-Y., Barker, H., Jasin, M., Prakash, R., Kass, E. M., Sullivan, M. R., Brunette, G. J., Bernstein, K. A., Coleman, R. L., Floquet, A., Fried Tags: Research Briefs Source Type: research
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations [Research Briefs]
This study highlights the importance of inclusion of underrepresented minorities in cancer sequencing studies. Cancer Discov; 7(9); 973–83. ©2017 AACR.
This article is highlighted in the In This Issue feature, p. 920 (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Authors: Huang, F. W., Mosquera, J. M., Garofalo, A., Oh, C., Baco, M., Amin-Mansour, A., Rabasha, B., Bahl, S., Mullane, S. A., Robinson, B. D., Aldubayan, S., Khani, F., Karir, B., Kim, E., Chimene-Weiss, J., Hofree, M., Romanel, A., Osborne, J. R., Kim, J. W., Tags: Research Briefs Source Type: research
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors [Research Briefs]
This article is highlighted in the In This Issue feature, p. 920 (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Authors: Drilon, A., Nagasubramanian, R., Blake, J. F., Ku, N., Tuch, B. B., Ebata, K., Smith, S., Lauriault, V., Kolakowski, G. R., Brandhuber, B. J., Larsen, P. D., Bouhana, K. S., Winski, S. L., Hamor, R., Wu, W.-I., Parker, A., Morales, T. H., Sullivan, F. X., Tags: Research Briefs Source Type: research
New Horizons for Precision Medicine in Biliary Tract Cancers [Review]
Biliary tract cancers (BTC), including cholangiocarcinoma and gallbladder cancer, are poor-prognosis and low-incidence cancers, although the incidence of intrahepatic cholangiocarcinoma is rising. A minority of patients present with resectable disease but relapse rates are high; benefit from adjuvant capecitabine chemotherapy has been demonstrated. Cisplatin/gemcitabine combination chemotherapy has emerged as the reference first-line treatment regimen; there is no standard second-line therapy. Selected patients may be suitable for liver-directed therapy (e.g., radioembolization or external beam radiation), pending confirma...
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Authors: Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J., Zhu, A. X. Tags: Review Source Type: research
